LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics N.V.

A biotechnology company focused on developing gamma delta T cell engagers to potently and precisely fight cancer.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		3.92M -	5M 27.60%	19.39M 287.82%	6.77M 65.09%
cost of revenue					3.48M -
gross profit		3.92M -	5M 27.60%	19.39M 287.82%	3.29M 83.05%
selling and marketing expenses
general and administrative expenses	1.24M -	2.88M 133.25%	12.16M 321.78%	14.12M 16.15%	12.73M 9.90%
selling general and administrative expenses	1.24M -	2.88M 133.25%	12.16M 321.78%	14.12M 16.15%	12.73M 9.90%
research and development expenses	8.35M -	16.78M 100.97%	37.19M 121.71%	40.10M 7.83%	33.81M 15.69%
other expenses		-0.00 -		3.18M -
cost and expenses	9.58M -	19.66M 105.14%	49.35M 151.05%	54.23M 9.88%	50.02M 7.76%
operating expenses	9.58M -	19.66M 105.14%	49.35M 151.05%	54.23M 9.88%	46.54M 14.18%
interest expense	86K -	361.61K 320.47%	625K 72.84%	82K 86.88%	232K 182.93%
ebitda	-9.32M -	-15.25M 63.51%	-44.35M 190.93%	-33.72M 23.98%	-38.77M 14.99%
operating income	-9.58M -	-15.74M 64.25%	-44.35M 181.79%	-34.84M 21.45%	-43.25M 24.15%
depreciation and amortization	259K -	494.44K 90.90%	558K 12.85%	1.12M 100.72%	1.28M 14.11%
total other income expenses net	-104K -	-924.92K 789.35%	-837K 9.51%	3.18M 479.93%	-1.41M 144.40%
income before tax	-9.69M -	-16.66M 72.03%	-45.19M 171.17%	-31.66M 29.94%	-41.70M 31.70%
income tax expense	86K -	43.05K 49.94%	157K 264.71%	249K 58.60%	279K 12.05%
net income	-9.77M -	-16.71M 70.96%	-45.35M 171.41%	-31.91M 29.64%	-41.97M 31.55%
weighted average shs out	18.41M -	25.35M 37.68%	19.76M 22.07%	25.92M 31.21%	26.73M 3.12%
weighted average shs out dil	18.41M -	25.35M 37.68%	19.76M 22.07%	25.92M 31.21%	26.73M 3.12%
eps	-0.53 -	-0.66 24.53%	-2.30 248.48%	-1.23 46.52%	-1.57 27.64%
epsdiluted	-0.53 -	-0.66 24.53%	-2.30 248.48%	-1.23 46.52%	-1.57 27.64%

NASDAQ:LVTX

Lava Therapeutics

Last Close

1.66

25/09 13:46

Market Cap

50.22M

Beta: −0.50

Volume Today

2.64K

Avg: 70.82K

PE Ratio

−0.89

PFCF: 7.59

Preview